Clinical trial
Definition and Validation of an Immune Signature Predictive of Anti-PD1 Antibody Used Alone or an Association With antiCTLA4 in the Treatment of Advanced Melanoma : PREDIMEL
NCT02938728 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Definition and Validation of an Immune Signature Predictive of Anti-PD1 Antibody Used Alone or an Association With antiCTLA4 in the Treatment of Advanced Melanoma : PREDIMEL
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- November 30, 2016
- Completion date
- March 31, 2021
- Enrollment
- 120 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
malignant melanoma